WHO says toxic syrup risk 'ongoing', more countries hit

[June 17, 2023]  By Jennifer Rigby

LONDON (Reuters) - There is an ongoing global threat posed by toxic cough syrups, the World Health Organization (WHO) told Reuters, saying it was now working with six more countries than previously revealed to track the potentially deadly children's medicines.

The U.N. agency has already named nine countries where tainted syrups may have been on sale, after the deaths of more than 300 infants on three continents last year were linked to the drugs.

Rutendo Kuwana, the WHO team lead for incidents with substandard and falsified medicines, declined to name the six new countries the agency is working with, while investigations are still underway.

He warned that contaminated medicines could still be found for several years, because adulterated barrels of an essential ingredient may remain in warehouses. Cough syrups and the ingredient, propylene glycol, both have shelf-lives of around two years.

"This is an ongoing risk," said Kuwana.

Unscrupulous actors sometimes substitute propylene glycol with toxic alternatives, ethylene glycol and diethylene glycol, because they are cheaper, several pharmaceutical manufacturing experts told Reuters.

The alternatives are more commonly used in brake fluid and other products not meant for human consumption.

The WHO's working theory is that in 2021, when prices of propylene glycol spiked, one or more suppliers mixed the cheaper toxic liquids with the legitimate chemical, Kuwana said. He did not say where the suppliers were based, and added that obscure supply chains have made proving this difficult.

Pharmaceutical manufacturers, including those alleged to have produced the tainted syrups that have been found so far, typically source ingredients from external suppliers.

LIBERIA AND CAMEROON

Earlier this week, Nigeria's regulator issued a warning about contaminated paracetamol syrups sold in Liberia, although no deaths have been reported there. The Nigerian regulator was testing the syrups, which were not sold in Nigeria, because Liberia has no testing facilities.

The WHO issued safety alerts last year for Indian-made products found in Gambia and Uzbekistan, and this year in Micronesia and the Marshall Islands.

It also issued an alert last year for Indonesian-made syrups that were only sold domestically. Indonesian authorities say more than 200 children were likely poisoned by these.

Three Indonesian-based manufacturers – PT Yarindo Farmatama, PT Universal Pharmaceutical Industries, PT AFI Farma – have had their licences revoked. A fourth, PT Konimex, said it had recalled all of the relevant products and its website says it was cleared by the Indonesian regulator to sell new batches as of December 2022. The Indonesian regulator did not immediately respond to a request for comment.

In January, the WHO named four other countries it was working with – Timor Leste, Cambodia, Senegal and the Philippines – to track whether any of the tainted syrups had reached their markets.

There is no current risk to the population in the countries the WHO has named, Kuwana said, either because contaminated medicines had been pulled from shelves or because they never reached the market in the first place.

The World Health Organisation (WHO) logo is seen near its headquarters in Geneva, Switzerland, February 2, 2023. REUTERS/Denis Balibouse/File Photo

The countries' governments either confirmed this, said there was only a minimal risk, or did not respond to requests for comment.

The WHO said it has also offered help to Liberia and Cameroon – which recently signalled that it too may have contaminated cough syrups for sale.

Cameroon's health regulator said in April it was investigating the deaths of six children linked to a cough syrup branded as Naturcold. The manufacturer named on the packet is China's Fraken Group, which did not immediately respond to requests for comment.

But the Cameroon authorities said in an alert the medicine was bought from unauthorised sources and possibly smuggled in. They did not respond to requests for more information.

Other manufacturers identified in the current spate of incidents are largely Indian-based. Two companies whose products have been linked to deaths have been shuttered by the authorities there: Maiden Pharmaceuticals, which sold syrups to Gambia, and Marion Biotech, whose syrups went to Uzbekistan.

Naresh Kumar Goyal, the founder of Maiden Pharmaceuticals, told Reuters in December his company did nothing wrong in the production of the cough syrup. Marion Biotech has not responded to requests for comment.

Besides these cases, Indian-made medicines supplied to the Marshall Islands and Micronesia have been recalled after Australian laboratory tests showing contamination prompted a WHO safety alert. The manufacturer, QP Pharmachem, told Reuters earlier this year that its own tests had found no issues.

The contaminated syrups in Liberia were made by India's Synercare Mumbai, according to the Nigerian regulator. The Liberian health regulator said it plans to incinerate the stock and will recall two other Synercare products as well, as a precaution.

Synercare did not respond to a request for comment.

NOT RECOMMENDED

Since 2001, the WHO has recommended against giving cough syrups to children aged under 5, because it says there is limited evidence of how effective they are, or what side-effects they may have.

There have also been at least five incidents in the last half century when paracetamol and cough medicines were contaminated with deadly chemicals, in countries including India and Panama, although the spate of deaths last year is the deadliest on record.

The WHO has also urged all countries to step up surveillance and offered support to concerned countries that do not have the resources to test their own medicines.

"It's not over certainly," said Kuwana. "But we don't need to panic, as a lot of countries are now being proactive."

(Reporting by Jennifer Rigby; additional reporting by Krishna N.Das in Delhi, Edward McAllister in Dakar, Stanley Widianto in Jakarta, Sumit Khanna in Ahmedabad, Sophie Yu in Beijing. Editing by Sara Ledwith and Michele Gershberg)

[© 2023 Thomson Reuters. All rights reserved.]This material may not be published, broadcast, rewritten or redistributed.  Thompson Reuters is solely responsible for this content.